<p>長期以來，醫療保健行業一直是經濟的重要組成部分。根據麥肯錫公司的一份報告，預計醫療保健行業在 2022 年至 2027 年間將以 7% 的速度增長。許多醫療公司嚴重依賴臨牀試驗，這些試驗需要獲得 FDA 批准才能上市。這使得預測公司未來表現變得極為困難。成功的試驗可能帶來數十億美元的收入。然而，一次失敗的試驗很可能會導致股價下跌。因此，對於投資者來説，提前做好研究，只購買具有高增長潛力的醫療股票至關重要。以下是投資者現在應該購買的三家最佳醫療股票。</p>
<h2>百時美施貴寶（BMY）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>圖片來源：Piotr Swat / Shutterstock.com</p>
<p>我們推薦的最佳醫療股票之一是 <strong>百時美施貴寶</strong>（紐約證券交易所：<strong>BMY</strong>）。這家制藥巨頭一直穩居市場前列，擁有多款藥物每年創造數十億美元的收入。此外，百時美施貴寶目前有多款藥物正在臨牀試驗中，未來十年可能取得巨大成功。其中包括治療精神分裂症的 Eliquis KarXT。預計該藥物將在下個月獲得 FDA 的推薦。如果獲批，它將成為首個新開發的精神分裂症治療藥物。據估計，這個市場在短短四年內將增長到超過 70 億美元。目前，該股今年下跌超過 10%，同比下跌 20%。投資者應該在股價下跌時購買。</p>
<h2>AMN 醫療服務（AMN）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>圖片來源：Casimiro PT / Shutterstock.com</p>
<p><strong>AMN 醫療服務</strong>（紐約證券交易所：<strong>AMN</strong>）是一家醫療護理設施公司。它提供醫療工作者，包括護士和行業專業人士，以臨時方式供職。在醫療工作者短缺時，由於高需求，公司取得了巨大成功。對於那些尋找高風險、高回報醫療股票的投資者，AMN 應該在他們的關注列表中。</p>
<p>公司最近的財報看起來非常有前景。在 2024 年第二季度，AMN 每股收益為 98 美分，幾乎比分析師預期高出 20 美分。這是 AMN 醫療服務連續第四個季度超過盈利預期。此外，AMN 的前瞻市盈率為 13.64 倍，低於市場上大多數競爭對手。在股價回升至 2022 年的最高價之前，投資者應該購買該股。</p>
<h2>Rapport Therapeutics（RAPP）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>圖片來源：Shutterstock</p>
<p>名單上的最後一支股票是 <strong>Rapport Therapeutics</strong>（納斯達克：<strong>RAPP</strong>），一家由 <strong>強生</strong>（紐約證券交易所：<strong>JNJ</strong>）支持的生物技術公司。該公司於今年 6 月 7 日上市，首次公開發行籌集了 1.54 億美元。股價在上市首日超過 20 美元，截至目前，股價為 19.05 美元。雖然對這家新進入市場的公司還有很多需要了解的地方，但肯定會吸引許多投資者。</p>
<p>Rapport Therapists 目前正在開發一種專注性癲癇藥物。第二階段試驗將在未來幾個月開始，這意味着這家生物技術初創公司未來幾年將會有令人興奮的消息。特別是考慮到僅在美國就有超過三百萬成年癲癇患者，這意味着這是一個有待探索的龐大市場。</p>
<p>_在本文發佈日期，Andy Kim 在本文提及的證券中沒有（直接或間接）任何持倉。本文中表達的觀點屬於作者本人，遵守 InvestorPlace.com 的發佈準則。</p>
<p>_在本文發佈日期，負責編輯在本文提及的證券中沒有（直接或間接）任何持倉。</p>
<p>Andy 是一位自學投資者，對 ESG 和社會責任投資感興趣。他管理過一家小型投資基金的投資組合，並創辦了自己的研究公司。通過在 InvestorPlace 的自由撰稿，他希望找到並分享有前景的公司投資，以改善世界。</p>
<p>生物技術，醫療保健</p>

百時美施貴寶

<p>醫療保健行業預計在 2022 年至 2027 年間以 7% 的速度增長，使其成為投資者感興趣的領域。三支值得考慮購買的醫療保健股票包括百時美施貴寶（BMY）、AMN 醫療服務（AMN）和 Rapport Therapeutics（RAPP）。百時美施貴寶在臨牀試驗中擁有有前途的藥物，而 AMN 醫療服務一直穩定地超過盈利預期。得到強生公司支持的 Rapport Therapeutics 正在開發一種專注性癲癇藥物。這些股票在醫療保健行業具有高增長潛力</p>

<p>The healthcare industry has been a critical part of the economy for a long time. According to a McKinsey &amp; Company report, the healthcare industry is expected to grow at 7% from 2022 to 2027. Many healthcare companies heavily rely on trials, which need to be FDA approved in order to be put on the market. This makes it extremely hard to predict a company’s future performance. Successful trials could bring in potentially billions of dollars in revenue. However, a failed trial will likely result in stock-price decline. Thus, it is extremely important for investors to do prior research and only buy healthcare stocks with high growth potential. Below are the three best healthcare stocks investors should buy right now.</p>
<div class="lb-trans"><p>長期以來，醫療保健行業一直是經濟的重要組成部分。根據麥肯錫公司的一份報告，預計醫療保健行業在 2022 年至 2027 年間將以 7% 的速度增長。許多醫療公司嚴重依賴臨牀試驗，這些試驗需要獲得 FDA 批准才能上市。這使得預測公司未來表現變得極為困難。成功的試驗可能帶來數十億美元的收入。然而，一次失敗的試驗很可能會導致股價下跌。因此，對於投資者來説，提前做好研究，只購買具有高增長潛力的醫療股票至關重要。以下是投資者現在應該購買的三家最佳醫療股票。</p>
</div><h2>Bristol-Myers Squibb (BMY)</h2>
<div class="lb-trans"><h2>百時美施貴寶（BMY）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Piotr Swat / Shutterstock.com</p>
<div class="lb-trans"><p>圖片來源：Piotr Swat / Shutterstock.com</p>
</div><p>The first stock on our list of the best healthcare stocks to buy is <strong>Bristol-Myers Squibb</strong> (NYSE: <strong>BMY</strong>). The pharmaceutical powerhouse consistently ranks as one of the top companies on the market, and has several drugs that generate billions of dollars in revenue. Furthermore, Bristol-Myers Squibb has a number of drugs currently in clinical trials that could bring in huge success over the next decade. Among these is schizophrenia treatment Eliquis KarXT. The drug is expected to receive a recommendation from the FDA as early as next month. If it gets approved, it will be the first newly developed treatment for schizophrenia. That is a market that is estimated to grow to more than $7 billion in just four years. Right now, the stock is down over 10% this year alone and 20% year-over-year. Investors should buy while the stock is down.</p>
<div class="lb-trans"><p>我們推薦的最佳醫療股票之一是 <strong>百時美施貴寶</strong>（紐約證券交易所：<strong>BMY</strong>）。這家制藥巨頭一直穩居市場前列，擁有多款藥物每年創造數十億美元的收入。此外，百時美施貴寶目前有多款藥物正在臨牀試驗中，未來十年可能取得巨大成功。其中包括治療精神分裂症的 Eliquis KarXT。預計該藥物將在下個月獲得 FDA 的推薦。如果獲批，它將成為首個新開發的精神分裂症治療藥物。據估計，這個市場在短短四年內將增長到超過 70 億美元。目前，該股今年下跌超過 10%，同比下跌 20%。投資者應該在股價下跌時購買。</p>
</div><h2>AMN Healthcare Services (AMN)</h2>
<div class="lb-trans"><h2>AMN 醫療服務（AMN）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Casimiro PT / Shutterstock.com</p>
<div class="lb-trans"><p>圖片來源：Casimiro PT / Shutterstock.com</p>
</div><p><strong>AMN Healthcare Services</strong> (NYSE: <strong>AMN</strong>) is a medical care facilities company. It supplies healthcare workers, including nurses and industry professionals, on a temporary basis. It experienced huge success from high healthcare worker demand when there was a worker shortage. For those investors who are looking for high-risk, high-reward healthcare stocks, AMN should be on their radar.</p>
<div class="lb-trans"><p><strong>AMN 醫療服務</strong>（紐約證券交易所：<strong>AMN</strong>）是一家醫療護理設施公司。它提供醫療工作者，包括護士和行業專業人士，以臨時方式供職。在醫療工作者短缺時，由於高需求，公司取得了巨大成功。對於那些尋找高風險、高回報醫療股票的投資者，AMN 應該在他們的關注列表中。</p>
</div><p>The company’s recent earnings reports look very promising. In Q2 2024, AMN reported earnings per share (EPS) of 98 cents, beating analyst’s estimates by almost 20 cents. This was the fourth consecutive quarter that AMN Healthcare Services beat the earnings estimate. Furthermore, AMN trades at 13.64 times forward price to earnings ratio, which is lower than the majority of its competitors in the market. Before it bounces back to its peak price from 2022, investors should buy the stock.</p>
<div class="lb-trans"><p>公司最近的財報看起來非常有前景。在 2024 年第二季度，AMN 每股收益為 98 美分，幾乎比分析師預期高出 20 美分。這是 AMN 醫療服務連續第四個季度超過盈利預期。此外，AMN 的前瞻市盈率為 13.64 倍，低於市場上大多數競爭對手。在股價回升至 2022 年的最高價之前，投資者應該購買該股。</p>
</div><h2>Rapport Therapeutics (RAPP)</h2>
<div class="lb-trans"><h2>Rapport Therapeutics（RAPP）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Shutterstock</p>
<div class="lb-trans"><p>圖片來源：Shutterstock</p>
</div><p>The last stock on the list is <strong>Rapport Therapeutics</strong> (NASDAQ: <strong>RAPP</strong>), a biotech company that is backed by <strong>Johnson &amp; Johnson</strong> (NYSE:<strong>JNJ</strong>). The company went public on June 7th of this year, and it raised $154 million in initial public offering. The stock price ended up to over $20 on the first day it went public, and as of writing, it goes for $19.05. While there is still lots to learn about the company as it is new to the market, there are certainly things that will attract many investors.</p>
<div class="lb-trans"><p>名單上的最後一支股票是 <strong>Rapport Therapeutics</strong>（納斯達克：<strong>RAPP</strong>），一家由 <strong>強生</strong>（紐約證券交易所：<strong>JNJ</strong>）支持的生物技術公司。該公司於今年 6 月 7 日上市，首次公開發行籌集了 1.54 億美元。股價在上市首日超過 20 美元，截至目前，股價為 19.05 美元。雖然對這家新進入市場的公司還有很多需要了解的地方，但肯定會吸引許多投資者。</p>
</div><p>Rapport Therapists is currently developing a focal epilepsy drug. The phase two trials should begin in the next few months, which means that there is going to be exciting news for the biotech startup for the upcoming years. This is especially exciting considering that in the U.S. alone, there are more than three million adult epilepsy patients, which means that it is a sizable market with room to explore.</p>
<div class="lb-trans"><p>Rapport Therapists 目前正在開發一種專注性癲癇藥物。第二階段試驗將在未來幾個月開始，這意味着這家生物技術初創公司未來幾年將會有令人興奮的消息。特別是考慮到僅在美國就有超過三百萬成年癲癇患者，這意味着這是一個有待探索的龐大市場。</p>
</div><p><em>On the date of publication, Andy Kim did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com</em> <em>Publishing Guidelines</em> <em>.</em></p>
<div class="lb-trans"><p>_在本文發佈日期，Andy Kim 在本文提及的證券中沒有（直接或間接）任何持倉。本文中表達的觀點屬於作者本人，遵守 InvestorPlace.com 的發佈準則。</p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p>_在本文發佈日期，負責編輯在本文提及的證券中沒有（直接或間接）任何持倉。</p>
</div><p>Andy is a self-taught investor who is interested in ESG and socially responsible investing. He has managed the portfolio of a small investment fund and started his own research firm. Through his freelance writing on InvestorPlace, he hopes to find and share promising investments in companies with the goal of bettering the world.</p>
<div class="lb-trans"><p>Andy 是一位自學投資者，對 ESG 和社會責任投資感興趣。他管理過一家小型投資基金的投資組合，並創辦了自己的研究公司。通過在 InvestorPlace 的自由撰稿，他希望找到並分享有前景的公司投資，以改善世界。</p>
</div><p>Biotech, Healthcare</p>
<div class="lb-trans"><p>生物技術，醫療保健</p>
</div>

2024 年 8 月最值得購買的三隻醫療股